National Bank of Canada FI Sells 98,755 Shares of IQVIA Holdings Inc. (NYSE:IQV)

National Bank of Canada FI trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 54.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 82,668 shares of the medical research company’s stock after selling 98,755 shares during the quarter. National Bank of Canada FI’s holdings in IQVIA were worth $16,245,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in IQV. Smith Group Asset Management LLC purchased a new stake in shares of IQVIA in the fourth quarter worth about $1,616,000. Nordea Investment Management AB raised its holdings in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Hickory Asset Management Inc. purchased a new position in shares of IQVIA in the fourth quarter valued at $941,000. Fifth Third Bancorp increased its position in IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after purchasing an additional 1,521 shares during the last quarter. Finally, Graphene Investments SAS raised its stake in IQVIA by 22.0% during the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock valued at $2,948,000 after purchasing an additional 2,700 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of IQV opened at $154.63 on Friday. The stock has a market capitalization of $27.26 billion, a PE ratio of 20.62, a PEG ratio of 1.99 and a beta of 1.46. The company has a 50 day moving average price of $189.67 and a 200-day moving average price of $204.07. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $154.35 and a fifty-two week high of $252.88.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IQV has been the topic of a number of research reports. JPMorgan Chase & Co. reduced their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. UBS Group lowered their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Stifel Nicolaus cut their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Barclays decreased their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Finally, Stephens initiated coverage on shares of IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.